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Abstract
Glioblastoma is the most aggressive brain tumor that may occur in adults. Regardless of the huge improvements in surgery
and molecular therapy, the outcome of neoplasia remains poor. MicroRNAs are small molecules involved in several cellular
processes, and their expression is altered in the vast majority of tumors. Several studies reported the expression of different
miRNAs in glioblastoma, but one of the most critical point in understanding glioblastoma miRNAs profile is the comparison
of these studies. In this paper, we focused our attention on the non-neoplastic references used for determining miRNAs
expression. The aim of this study was to investigate if using three different non-neoplastic brain references (normal adjacent
the tumor, commercial total RNA, and epileptic specimens) could provide discrepant results. The analysis of 19 miRNAs was
performed using Real-Time PCR, starting from the set of samples described above and the expression values compared.
Moreover, the three different normal RNAs were used to determine the miRNAs profile in 30 glioblastomas. The data
showed that different non-neoplastic controls could lead to different results and emphasize the importance of comparing
miRNAs profiles obtained using the same experimental condition.
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Introduction
MicroRNAs (miRNAs) are small RNA molecules involved in
several cellular processes. Briefly, these small RNAs regulate
proteins expression by binding target mRNAs with a perfect or
imperfect complementarity [1]. The miRNAs expression analysis
could be performed using different techniques, such as microarray
assays or Real-Time PCR. Regardless of the chosen approach, one
of the most important decisions before analyzing miRNAs profile
(as well as for mRNAs expression studies) is the selection of a
reference control. The availability of non-neoplastic specimens
used as reference is often subordinated to understudied tissue.
Differently from what happens for other tissues such as breast or
lung [2–4], obtaining brain specimens from healthy subjects is very
difficult and, therefore, finding a suitable non-neoplastic control
for the analysis of RNA in brain neoplasia still remains a big issue.
Moreover, for surgical neoplastic brain samples, the non-
neoplastic area is usually absent, very limited, or adjacent the
tumor, as for glioblastoma (GBM).
This study was conducted within the PERNO (Progetto
Emiliano-Romagnolo di Neuro-Oncologia) project. One of the
goals of PERNO is to investigate the role of miRNAs in GBM. In
a previous paper [5], we demonstrated the feasibility of miRNAs
analysis in brain specimens starting from formalin-fixed and
paraffin-embedded tissues (FFPE), as well as in fresh/frozen
samples. In literature, there are at least three different specimens
used as normal reference for miRNAs analysis in brain samples:
the normal area adjacent the tumor [6–8], one of the available
commercial references (FirstChoiceH Human Brain Reference
RNA, Ambion) [9,10], and the tissue removed in epileptic patients
[11,12]. Before looking for miRNAs profile in GBM, we decided
to deeply investigate the miRNAs expression values in these three
different non-neoplastic RNAs.
The aim of this study was to compare three different references
used as non-neoplastic control for miRNAs analysis in GBM (the
normal area adjacent the tumor, a commercial reference, and the
tissue removed in epileptic patients) by investigating the expression
levels of nineteen miRNAs. In order to clarify if the choice of non-
neoplastic samples could influence the miRNAs analysis in GBM,
the miRNAs profiles of thirty GBMs were also investigated using
each one of the three references as control.
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Materials and Methods
Ethic Statement
The study was approved by Ethic Committee of Azienda
Sanitaria Locale di Bologna (number of study 08075, protocol
number 139/CE of 5th February 2009, Bologna, Italy). All patients
signed a written consent for molecular analysis and anonymous
data publication for scientific studies, and all information
regarding the human material used in this study was managed
using anonymous numerical codes.
Selection of Cases
MicroRNAs expression analysis was performed using a com-
mercial brain reference (FirstChoiceH Human Brain Reference
RNA, Ambion, Austin, TX, USA), 15 cases of normal samples
adjacent the tumor and 15 cases of polar temporal cortical (PTC)
specimens removed in patients submitted to surgery (tailored polar
anterior temporal resection along with uncus-amygdalohippocam-
pectomy) for drug-resistant epilepsy. All the cases were retrieved at
Bellaria Hospital (Section of Pathology, Bologna, Italy), and
normal samples adjacent the tumor specimens were included
within the PERNO project.
Normal adjacent the tumor. Normal adjacent the tumor
tissues were retrieved at a distance between 1 and 2 cm from the
margin of 15 primary FFPE GBMs. Patients were 8 males and 7
females, aged 50 to 75 years (mean 62.7 yrs). All samples were
diagnosed as GBM according to the 2007 WHO criteria [13].
Thirty samples were also used for the GBMs profile (see below).
Commercial reference. The FirstChoiceH Human Brain
Reference RNA from Ambion was used. According to the
manufacturers’ data sheet, it was obtained from several normal
brain regions (meaning free of brain pathology) of 23 donors, 13
males and 10 females, aged 23 to 86 (mean 69.7 yrs). FirstChoiceH
is certified to contain small RNAs, including miRNAs.
Epileptic tissue. Fifteen FFPE PTC samples were randomly
selected. Epileptic patients were 7 males and 8 females, aged 25 to
52 years (mean 39.7 yrs). All of them presented drug-resistant
anteromedial temporal lobe epilepsy. Histologically, eleven cases
showed focal cortical dysplasia while four patients had hippocam-
pal sclerosis. None of them were affected by a neoplastic lesion,
including GBM. The tissue used for miRNAs extraction was taken
from the temporal lobe cortex.
Glioblastoma. Thirty patients were selected for determining
GBMs profile using the three different non-neoplastic references.
All specimens were primary GBMs, and patients had not
undergone neoadjuvant therapy before surgery. Patients were 14
males and 16 females, aged 42 to 75 years (mean 63.3 yrs). All
samples were diagnosed as GBM according to the 2007 WHO
criteria [13].
miRNAs Analysis
The hematoxylin and eosin (H&E) sections were reviewed by a
pathologist (GM) to select the more informative block. Four 20
mm-thick sections were cut, followed by one H&E control slide.
The area selected for the analysis was marked on the control slide
to ensure, whenever possible, greater than 90% content of glial
cells (normal adjacent the tumor and epileptic specimens) or
neoplastic cells (glioblastoma samples).
Nineteen miRNAs (miR-7, miR-9, miR-9*, miR10a, miR10b,
miR-17, miR-20a, miR-21, miR-26a, miR-27a, miR-31, miR-
34a, miR-101, miR-137, miR-182, miR-221, miR-222, miR-330,
miR-519d) were studied according to their role in GBM and
because of their previous technical validation in order to
determine the feasibility of analysis starting from FFPE tissues
[5]. Three small RNAs (RNU49, U54, miR-103) were used as
internal control [5]. The miRNAs extraction and analysis were
performed as previously described [5]. Briefly, RNA was retro-
transcribed using the NCode miRNA First-Strand cDNA Synthe-
sis and qRT-PCR Kits (Invitrogen, Carlsbad, CA, USA), and
miRNAs expression was evaluated using an AB7000 machine
(Applied Biosystem, Foster City, CA, USA). Each miRNA was run
twice per each sample. Considering that commercial reference was
a pool of RNA obtained from normal brain, it was analyzed three
times (technical replicates).
Statistical Analysis
Expression values and fold changes were obtained by relative
quantification and 22DDCT method [14] using the DataAssist 2.0
Tool (Applied Biosystem, Foster City, CA, USA). In order to
determine miRNAs profile obtained in GBM, the median fold-
change of each miRNA in the 30 GBM samples was compared
with ‘‘control samples’’ (15 epileptic specimens, 14 normal
adjacent tissues and 1 commercial reference). A GBM/Control
ratio ,22.0 means that miRNA was downregulated, while a ratio
$2.0 means that miRNA was upregulated. Statistical analysis of
miRNAs expression was performed using GraphPad Prism 5.0
tool. Gaussian distribution was evaluated by Shapiro-Wilk Test.
Correlation analysis between miRNAs expression in the three
different groups were performed using Spearman correlation test.
For comparing the expression levels of each miRNA obtained in
the three groups, Kruskal-Wallis and Mann-Whitney tests were
used. Level of significance was p,0.05 for all the statistical
analysis.
Results
All the samples, except one normal adjacent the tumor
specimen, gave sufficient quantity of miRNAs for performing the
analysis.
miRNAs Analysis in Normal References
Distribution for normal adjacent the tumor, commercial
reference, and epileptic groups was not Gaussian as demonstrated
by the Shapiro Test (p,0.001). For this reason, we used non-
parametric statistical tests.
All Spearman correlation values between the expression levels
of each miRNAs obtained in the three groups were above 0.65
(p,0.0001) (Table 1).
While comparing the median expression values obtained in the
three different groups, we observed statistical significant differ-
ences (p,0.05) in 9 miRNAs: miR-7, miR-9, miR-10a, miR-10b,
miR-26a, miR-27a, miR-31, miR-137, and miR-182. For the
others, no significant differences were observed (Table S1).
Moreover, the Mann-Whitney test, performed considering groups
in pairs, revealed statistical significant differences even in miR-101
and miR-519d, as shown in Figure 1. It should be considered that
the variability observed in normal adjacent the tumor and in
epileptic specimens is a biological variability, while the one
observed in commercial reference (a pool of normal brain RNA) is
a technical variability.
GBM Profile
The differences observed when comparing expression values of
miRNAs in the three different references led us to further
investigate if the choice of non-neoplastic control could give
discrepant results in analyzing GBM miRNAs profile. For this
reason, we compared the profile of the 19 miRNAs in thirty GBMs
matched with the three different non-neoplastic brain references
MiRNAs Expression in Brain References
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(normal adjacent the tumor, commercial reference, and epileptic
tissue).
Using different non-neoplastic reference groups resulted in
different GBM miRNAs expression profiles (Table 2 and
Figure S1). For example, miR-17 was up-regulated (FC $2.0) in
GBM when matched with Ambion reference, but was not
deregulated when matched with normal adjacent the tumor or
epileptic tissue; miR-31 was down-regulated (FC,22.0) in GBMs
matched with Ambion reference and normal adjacent the tumor,
but not deregulated when matched with epileptic tissue. Other
miRNAs with different expression status were miR-10a, miR-10b,
miR-20a, miR-26a, miR-27a, miR-34a, miR-101, miR-182, miR-
221, miR-222, and miR-330, as shown in Table 2.
The remnant miRNAs (miR-7, miR-9, miR-9*, miR-21, miR-
137, miR-519d) showed the same expression profile in the three
groups even if differences in the level of up- or down-regulation
could be observed (Table 2).
Discussion
GBM is the most aggressive brain tumor that may occur in
adults. Nevertheless, there were improvements in surgery,
radiotherapy, chemotherapy, and ‘‘target therapy’’ [15], while its
prognosis remains poor [13,16]. MicroRNAs expression seems to
play an important role in cancer development and progression and
could be a possible target for molecular therapy [17]. For this
reason, identifying a miRNAs profile in GBM could be very useful
in developing new drugs and therapeutic approaches. The starting
material and samples used as reference control are two crucial
points for expression study design. In a previous study, the authors
demonstrated that miRNAs analysis in GBM is feasible in FFPE
samples, as well as in fresh/frozen ones [5]. Due to the difficulty of
gathering non-neoplastic brain specimens, in literature, there are
Table 1. Spearman correlation values between three groups
(p,0.0001).
Normal Adjacent
Tumor
Ambion Brain
Reference
Epileptic
Tissue
Normal Adjacent Tumor / 0.724 0.702
Ambion Brain Reference 0.724 / 0.848
Epileptic Tissue 0.702 0.848 /
doi:10.1371/journal.pone.0055314.t001
Figure 1. Differences in miRNAs expression. Scatter plots show miRNAs significantly different between groups. Bars indicate median values. *
p,0.05, ** p,0.01 according to Mann-Whitney test. The representation of commercial reference (a pool of normal brain RNA) indicates technical
variability, while scatter plots of Normal adjacent the tumor and epileptic specimens show individual variability. N-Ad, Normal adjacent the tumor;
Ref, Commercial reference; EP, epileptic.
doi:10.1371/journal.pone.0055314.g001
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different samples chosen as reference control in miRNAs
expression analysis (e.g. normal adjacent tissues [6–8] or epileptic
samples [11,17]). Moreover, several commercial pools of RNAs
obtained from normal brain tissues were available, such as the
Ambion FirstChoiceH Human Brain Reference RNA [6,16]. This
situation led each group to arbitrarily choose a reference,
sometimes obtaining different miRNAs expression profiles accord-
ing to selected control [18].
In our study, we investigated if miRNAs expression profiles
obtained using different non-neoplastic controls are comparable or
not. For this reason, normal samples adjacent the tumor,
commercial reference (FirstChoiceH Human Brain Reference
RNA – Ambion), and epileptic samples were used. Although
microarrays are a widescreen and powerful method for miRNAs
analysis, we focused on the 19 miRNAs previously analyzed and
validated in order to determine the feasibility of analysis starting
from both fresh frozen and FFPE tissues [5].
Before analyzing miRNAs expression data, some technical
issues regarding the present study should be considered. The mean
age of the epileptic group was significantly different from that of
the others, as expected considering mean age of epilepsy onset.
The commercial reference was a pool of RNAs obtained from
multiple donors and several brain regions, while RNAs from other
non-neoplastic groups (normal adjacent tissue and epileptic
specimens) were not pooled together; for this reason, the replicates
obtained from commercial reference represented technical repli-
cates, while those obtained from the other groups were evaluated
as biological replicates. Bearing in mind these issues, it should be
considered that the aim of the present study was to determine
whether GBM miRNAs profile shows differences using several
non-neoplastic references. For this reason we reproduced three
experimental conditions with normal adjacent tissues, commercial
references or epileptic specimens as non-neoplastic controls.
The comparison between expression values of miRNA obtained
in each of the three groups revealed good correlation values
(.0.65). However, the correlation value was higher when
comparing epileptic and commercial reference (R: 0.848).
Meanwhile, when epileptic group and commercial reference were
compared with normal adjacent the tumor, the correlation values
were lower (R: 0.702 and 0.724, respectively). This could be due to
the fact that the miRNAs expression profile of normal adjacent the
tumor tissue could be influenced by the surrounding neoplastic
cells, just as what happened during mRNA expression analysis
experiments [19].
While comparing the median expression values of each
miRNAs obtained in the three different groups, we observed
some statistical significant differences (p,0.05) in several miRNAs
(miR-7, miR-9, miR-10a, miR-10b, miR-26a, miR-27a, miR-31,
miR-101, miR-137, miR-182, miR-519d).
Bearing in mind this evidence, we analyzed 19 miRNAs in a
group of GBMs (thirty samples within the PERNO project cohort)
using the three previously described references as non-neoplastic
controls. We observed that miRNAs profiles obtained in these 30
GBMs were different according to the chosen control group. In
fact, no differences were observed in 6 miRNAs, while 13 out of 19
(miR-10a, miR-10b, miR-17, miR-20a, miR-26a, miR-27a, miR-
31, miR-34a, miR-101, miR-182, miR-221, miR-222, and miR-
330) showed a different modulation in GBM depending on a
selected reference, considering a cutoff of 2-fold change. More-
over, it should be noticed that, even in those miRNAs showing a
Table 2. MiRNAs profile in 30 GBMs compared with the 3 different non-neoplastic references.
miRNAs Normal adjacent Tumor Ambion Reference Epileptic
Median FC 6
Median Error Statusa N. of casesb
Median FC 6
Median Error Statusa N. of casesb
Median FC 6
Median Error Statusa N. of casesb
miR-7 27.37760.257 DOWN 24/30 211.08660.117 DOWN 27/30 223.75360.055 DOWN 28/30
miR-9 1.67960.671 = 14/30 21.40360.194 = 18/30 21.33160.290 = 20/30
miR-9* 1.85561.509 = 14/30 1.68460.936 = 18/30 1.52160.884 = 18/30
miR-10a 1.29660.494 = 16/30 1.07460.280 = 18/30 2.43660.954 UP 19/30
miR-10b 1.84461.111 = 9/30 3.10561.157 UP 21/30 4.68862.699 UP 23/30
miR-17 1.66061.620 = 18/30 2.03861.358 UP 16/30 1.96061.360 = 14/30
miR-20a 2.39660.729 UP 18/30 1.60660.334 = 18/30 2.21760.501 UP 17/30
miR-21 10.18063.602 UP 27/30 9.69462.343 UP 27/30 13.61465.270 UP 28/30
miR-26a 1.08061.346 = 21/30 25.97460.143 DOWN 28/30 21.45060.964 = 19/30
miR-27a 1.41960.339 = 22/30 2.99560.489 UP 23/30 2.92360.764 UP 23/30
miR-31 23.14260.775 DOWN 19/30 28.83861.471 DOWN 25/30 21.89161.041 = 11/30
miR-34a 1.02960.674 = 15/30 2.20560.983 UP 15/30 1.92861.481 = 14/30
miR-101 21.11660.675 = 20/30 22.46660.209 DOWN 18/30 22.65660.241 DOWN 19/30
miR-137 23.68160.075 DOWN 24/30 26.17560.031 DOWN 29/30 210.92960.308 DOWN 29/30
miR-182 21.04961.394 = 12/30 1.92461.923 = 11/30 4.73761.756 UP 21/30
miR-221 21.43160.951 = 15/30 21.26760.733 = 14/30 22.53260.447 DOWN 18/30
miR-222 210.23060.194 DOWN 26/30 21.98260.674 = 10/30 212.98760.152 DOWN 28/30
miR-330 24.76560.228 DOWN 24/30 21.71560.432 = 14/30 25.88260.156 DOWN 24/30
miR-519d 24.81360.238 DOWN 22/30 23.55260.220 DOWN 20/30 22.42160.326 DOWN 17/30
aStatus is determined according to Median Fold Change; b Number of GBMs showing the modulation out of a total of 5. FC: Fold change; UP: up-regulated (FC $2.0);
DOWN: down-regulated (FC ,22.0); = : not deregulated.
doi:10.1371/journal.pone.0055314.t002
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comparable status in the three groups, differences in fold change
values can be observed (e.g. miR-7, miR-137).
The differences in expression of some miRNAs in comparison
with other studies could be due to: 1) the enrichment in neoplastic
cells could give discrepant results with those obtained without
performing dissection [5]; 2) different reference controls could lead
to different miRNAs profiles as demonstrated in this study. An
example was the study by Malzkorn et al. [10] in which miR-9,
miR-17, miR-20a, and miR-21 showed an increased expression in
recurrent GBMs compared with primary grade II tumors.
Although a splendid approach and technique were used in the
study, it is not advisable to compare these results with ours, both in
agreement (e.g. mir-20a) and not (e.g. miR-9), because of a
different reference (primary grade II tumors) used by Malzkorn
et al. for determining the modulation of selected miRNAs.
Even though only 19 miRNAs were here considered, it is
reasonable to hypothesize that the same discrepancies could be
observed analyzing any miRNAs.
In conclusion, the present study shows that comparing miRNAs
profiles obtained using different non-neoplastic controls is not
recommended for several reasons: 1) the physiological differences
in mean age that could be observed between different groups (e.g.
epileptic specimens have a mean age lower than normal adjacent
the tumor samples); 2) technical issues: e.g. a commercial reference
is usually obtained pooling together several non-neoplastic RNAs
(technical variability), while RNAs obtained from normal adjacent
the tumour or epileptic specimens are not usually pooled together
(biological variability); 3) different selected non-neoplastic groups
could have real different miRNAs expression values. Having
considered that the number of GBMs analyzed in this study was
too small for determining a conclusive miRNAs profile (study in
progress), we emphasized that the results of miRNAs profile in
GBMs are strictly dependent on the non-neoplastic reference.
Supporting Information
Figure S1 miRNAs profile in 30 GBMs compared with the three
different non-neoplastic references. Lines in correspondence of
Median FC = +2 and 22 indicate the cut off for up- or down-
regulation, respectively. Bars indicate FC median errors. FC, Fold
change; N-Ad, Normal adjacent the tumor; Ref, Commercial
reference; EP, epileptic.
(TIF)
Table S1 Median expression values obtained in the three
different groups. *p-values were obtained using Kruskal-Wallis
test.
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